앨라배마의 주요우울장애 임상 시험
주요우울장애 관련 연구 15개가 앨라배마 내 여러 지역에서 참여자를 모집하고 있습니다.
앨라배마의 도시
공식 연구 텍스트(영어)
A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder
- University of Alabama at Birmingham - School of Medicine, Birmingham
피험자 모집 중3상
18세 ~ 75세 · 모든 성별 · 2026. 10. 1. 업데이트됨 · NCT07775300Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
- University of Alabama at Birmingham, Huntsville
피험자 모집 중3상
18세 ~ 65세 · 모든 성별 · 2026. 9. 25. 업데이트됨 · NCT05850689A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder
- University of Alabama at Birmingham, Birmingham
피험자 모집 중3상
12세 ~ 17세 · 모든 성별 · 2026. 9. 25. 업데이트됨 · NCT07227454A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
- UAB Psychiatry and Behavioral Neurology, Birmingham
피험자 모집 중3상
18세 ~ 85세 · 모든 성별 · 2026. 9. 25. 업데이트됨 · NCT06793397A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)
- University of Alabama at Birmingham, Huntsville Regional Medical Campus, Huntsville
피험자 모집 중3상
18세 ~ 74세 · 모든 성별 · 2026. 9. 8. 업데이트됨 · NCT07076407Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND)
- University of Alabama at Birmingham - Dept. of Psychiatry, Birmingham
피험자 모집 중
22세 ~ 70세 · 모든 성별 · 2026. 8. 28. 업데이트됨 · NCT06423430Psilocybin Intervention for Veterans Overcoming Treatment-Resistant Depression
- Birmingham VA Medical Center, Birmingham, AL, Birmingham
- Tuscaloosa VA Medical Center, Tuscaloosa, AL, Tuscaloosa
피험자 모집 중3상
18세 ~ 75세 · 모든 성별 · 2026. 8. 14. 업데이트됨 · NCT07226232NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
- Neurocrine Clinical Site, Huntsville
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 8. 11. 업데이트됨 · NCT06911112Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
- University of Alabama at Birmingham, Birmingham
피험자 모집 중2상
18세 ~ 64세 · 모든 성별 · 2026. 8. 3. 업데이트됨 · NCT06547489Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
- Neurocrine Clinical Site, Huntsville
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 7. 24. 업데이트됨 · NCT06966401Neural-Derived Plasma Exosomal MicroRNAs As Promising Novel Biomarkers for Suicidality and Treatment Outcome in Adolescents
- University of Alabama at Birmingham, Birmingham
- UAB Huntsville Regional Medical Campus, Huntsville
피험자 모집 중건강한 지원자 환영
10세 ~ 24세 · 모든 성별 · 2026. 7. 13. 업데이트됨 · NCT05437588A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder
- Harmonex /ID# 277517, Dothan
피험자 모집 중2상
18세 ~ 65세 · 모든 성별 · 2026. 6. 15. 업데이트됨 · NCT07276997MicroRNA Correlates of Childhood Maltreatment and Suicidality
- University of Alabama at Birmingham, Birmingham
- UAB Huntsville Regional Medical Campus, Huntsville
피험자 모집 중관찰 연구건강한 지원자 환영
18세 ~ 60세 · 모든 성별 · 2026. 3. 30. 업데이트됨 · NCT04923685Using TMS to Understand Neural Processes of Social Motivation
- Auburn University, Auburn
피험자 모집 중
25세 ~ 50세 · 모든 성별 · 2026. 3. 3. 업데이트됨 · NCT06274112Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY)
- Autobahn Site #131, Birmingham
피험자 모집 중2상
18세 ~ 65세 · 모든 성별 · 2026. 1. 20. 업데이트됨 · NCT06633016ClinicalTrials.gov 출처, 2026. 10. 5. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.